Dunstable GP surgery criticised over woman’s opioid death
A coroner says no plan was in place to reduce a women dosage of “dependency forming drugs”.
Similar Posts
Scientists Find About A Quarter Million Nanoplastic Particles In Bottled Water
The average liter of bottled water has nearly a quarter million invisible pieces of ever so tiny nanoplastics, detected and categorized for the first time by a microscope using dual lasers. Scientists long figured there were lots of these microscopic plastic pieces, but until researchers at Columbia and Rutgers universities did their calculations they never…
COVID infections on the rise as new year begins
COVID infections on the rise as new year begins – CBS News Watch CBS News A rise in COVID-19 infections has prompted at least five states to reinstate mask requirements at health care facilities. Elise Preston reports. Be the first to know Get browser notifications for breaking news, live events, and exclusive reporting. Not Now…
Benny T’s dry hot sauces recalled over undisclosed wheat allergy risk
Vesta Fiery Gourmet Foods is recalling several types of its Benny T’s dry hot sauces because the product labels do not disclose that the sauces contain wheat flour, a potential allergen. Â The recall comprises five flavors of chile pepper-based dry sauces that come in 1.5-ounce jars, the Raleigh, North Carolina-based food company said Monday…
Peanut death inquest told of restaurant’s blank allergy forms
An inquest hears a restaurant linked to a peanut allergy death had incomplete documentation.
These Women Spend Thousands Of Dollars To Medically Enlarge Their Clitorises
Before deciding whether to operate, Salgado studied the literature to find out if a larger clitoris led to increased sexual pleasure. He found a 2014 study in the Journal of Sexual Medicine that showed a correlation between women with larger clitorises and the ability to orgasm. But the study was small, with only 30 participants,…
Investors see a biotech comeback in 2024 as rates fall, deal-making picks up. Stocks to watch
Many biotech stocks struggled in 2023 despite a robust year for U.S. drug approvals. As these new therapies begin treating patients, some investors see better times ahead next year. “We’ve seen a lot of innovation,” Dan Lyons, portfolio manager on the health-care team at Janus Henderson, said, explaining that he is bullish on 2024 because…
